Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.
Liposomal doxorubicin and nab-paclitaxel are nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.
Gaitanis
Alexander
A
Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
Staal
Stephen
S
D000418:Albumins / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D008081:Liposomes; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*
C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D008081:Liposomes; D004317:Doxorubicin; D017239:Paclitaxel